Evidence map›Paper›PMID 29511861›Full record

ReviewCurrent cardiology reports2018

Myocardial Extracellular Volume Quantification by Cardiovascular Magnetic Resonance and Computed Tomography.

Paul R Scully, Gorka Bastarrika, James C Moon, Thomas A Treibel

Open access · hybridAbstract readReview
In one paragraph

Review in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cardiac amyloidosis: what every interventional cardiologist should know.Cardiovascular intervention and therapeutics · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Advanced myocardial characterization and function with cardiac CT.The international journal of cardiovascular imaging · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Paul R ScullyCardiac Imaging Department, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London, EC1A 7BE, UK.
Gorka BastarrikaClínica Universidad de Navarra, University of Navarra, Avda/Pio XII 55, 31008, Pamplona, Spain.
James C MoonCardiac Imaging Department, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London, EC1A 7BE, UK.
Thomas A TreibelCardiac Imaging Department, Barts Heart Centre, St Bartholomew's Hospital, 2nd Floor, King George V Building, West Smithfield, London, EC1A 7BE, UK. thomas.treibel@bartshealth.nhs.uk.
St Bartholomew's Hospital · GBClinica Universidad de Navarra · ESUniversity College London · GB

Funding

British Heart Foundation FS/16/31/32185Department of Health DRF-2013-06-102
6 · The paper itself

Abstract

purpose of reviewThis review article discusses the evolution of extracellular volume (ECV) quantification using both cardiovascular magnetic resonance (CMR) and computed tomography (CT). RECENT

findingsVisualizing diffuse myocardial fibrosis is challenging and until recently, was restricted to the domain of the pathologist. CMR and CT both use extravascular, extracellular contrast agents, permitting ECV measurement. The evidence base around ECV quantification by CMR is growing rapidly and just starting in CT. In conditions with high ECV (amyloid, oedema and fibrosis), this technique is already being used clinically and as a surrogate endpoint. Non-invasive diffuse fibrosis quantification is also generating new biological insights into key cardiac diseases. CMR and CT can estimate ECV and in turn diffuse myocardial fibrosis, obviating the need for invasive endomyocardial biopsy. CT is an attractive alternative to CMR particularly in those individuals with contraindications to the latter. Further studies are needed, particularly in CT.

Indexed as

Cardiomyopathy, HypertrophicContrast MediaExtracellular MatrixFibrosisGadolinium DTPAHeartHeart FailureHumansMagnetic Resonance ImagingMyocardial InfarctionMyocardiumTomography, X-Ray ComputedContrast MediaGadolinium DTPACardiovascular magnetic resonanceComputed tomographyExtracellular volumeTissue characterization

Identifiers

PMID29511861
PMCPMC5840231
OpenAlexW2792844680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.